Summit is focused on discovering and developing proprietary new drugs that target serious disease with a high unmet medical need.  Our high quality drug pipeline uses our scientific expertise to target a range of therapeutic areas including neurological disorders and infectious diseases.

Summit’s strategy is to generate value from our drug pipeline by developing programmes up to and including phase IIa clinical trials while seeking to sign early-stage licensing and partnering deals. 

Our two world-class technology platforms support the development of current drug programmes and will also help to identify new targets to refuel our pipeline in the future.